This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

Suicidal Ideation and Varenicline: A Possible Case of Mistaken Adverse Drug Reaction?

Lucy I. Spirling, MRCPsych; John A. Stapleton, MSc; and Gay Sutherland, MPhil

Published: November 30, 2008

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Varenicline, an a4ß2 nicotinic acetylcholine partial agonist,has been licensed in the United Kingdom (and approved inthe United States) for the treatment of tobacco dependencesince 2006. Studies have shown varenicline to result in highersmoking cessation rates over placebo, bupropion, and nicotinereplacement therapy (NRT). In the one study conducted todate, varenicline was also seen to be effective in smokers withmental illness, there being no evidence of excess adverse eventsor exacerbation of preexisting conditions.’ ‹


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 69

Quick Links: Depression (MDD) , Suicide